FDA Staff: No Compounding for BPC-157, TB-500, 5 More

FDA career scientists released their briefing documents ahead of the July 23-24 compounding advisory meeting — and they recommend against adding all seven peptides under review to the 503A Bulks List. The lineup: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon.

The documents landed around June 30-July 1, roughly three weeks earlier than the "no later than two business days before the meeting" window everyone expected. They are the clearest signal yet of where FDA staff stand — and they set up a direct clash with HHS Secretary Robert F. Kennedy Jr., who has pushed to expand peptide access and reshaped the advisory panel that will vote.

Research-context information only. BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon are research peptides sold for research purposes only. The regulatory details below come from public FDA records and reporting by NPR, US News, and NBC News. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

What the briefing documents actually say

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is deciding whether these seven belong on the 503A Bulk Drug Substances List — the list that would let compounding pharmacies prepare a peptide against an individual prescription. The docket is FDA-2025-N-6895. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c; Day 2 (July 24) covers Emideltide (DSIP), Semax, and Epitalon.

In the newly posted materials, FDA scientists argue that the available human studies for the seven peptides do not provide enough support on safety or effectiveness to meet the 503A standard. Their bottom-line recommendation, per reporting on the documents, is that none of the seven — nor their acetate salt forms — be added to the list.

The staff were bluntest on the wound-healing pair. For TB-500 and KPV, the peptides nominating groups pitched for tissue repair, reviewers wrote that they could not locate any studies in which the substances had been administered to humans at all. For the rest, staff flagged thin or inconsistent human data and open questions on identity and manufacturing characterization.

This is a staff recommendation, not a verdict. The PCAC is advisory: its members hear the evidence, take public comment, and vote substance by substance — the seven are not bundled, so they can split. The FDA then decides separately whether to start rulemaking. But an advisory panel rarely moves far past a unanimous "no" from the agency's own scientists, which is why these documents matter.

What this means for access — and what it doesn't

Here is the part the headlines bury: a negative recommendation does not re-criminalize anything. All seven peptides already came off the FDA's Category 2 "may not be compounded" list on April 23, 2026 — that reclassification is what teed up this review in the first place. The July vote is an upside question (does a new legal compounding channel open?), not a re-ban risk.

So the practical map for anyone sourcing these peptides is unchanged:

If the committee follows staff and votes no — the FDA simply declines to add a prescription-compounding pathway. Demand stays in the research-use-only channel, exactly where it is today.

If a peptide somehow gets a favorable vote — access still would not flip overnight. The FDA has to run formal rulemaking before any pharmacy can act, a process that realistically runs into 2027. Research-use-only supply remains the near-term route regardless.

Either way, the briefing documents change no pricing, no stock, and no availability for what people are actually buying this week. The compounded-pharmacy path, if it ever arrives, is a 2027 story at the earliest.

The one thing this development does change is expectation: the odds of a legal compounding channel opening in 2026 just dropped. Readers who were waiting on pharmacy access before sourcing BPC-157 or TB-500 now face an open-ended timeline — and the research-use-only market is the same market it was before the documents dropped.

Where to buy the peptides under review

Every one of the seven is carried by research-use-only vendors right now, and the FDA staff documents touch none of that pricing or availability. Compare live cost-per-mg, COA verification, and current coupons per peptide below — each card routes to that peptide's ranked vendor page.